Parallel Trade Considerable Risk to Patient Safety


The European Commission is to prioritise and speed up moves to deal with the issue of counterfeit drugs in parallel trade and will launch a legislative initiative on the issue after the summer break, Commission Vice President Guenter Verheugen has announced in the European Parliament.

At the end of December 2006, the Commission began a two-part study into pharmaceutical distribution channels. The first part of the study, dealing with safe medicines in parallel trade, was completed at the end of 2007 and the second, covering counterfeit medicines, was due to present this year.

21 January 2008

Read the full story at pharmatimes.com.